Conjunctival bacteria linked to higher fluoroquinolone resistance in new study from Brazil
Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said
Oculis shares phase 2 ACUITY results for novel neuroprotective therapy OCS-05
Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis
Regeneron acquires UK biotech company Oxular, broadening retina portfolio
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema
OCT and OCTA provide insights on neuroretinal changes associated with fibromyalgia
Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer
International RESTORE study produces results of genetic therapy for Leber hereditary optic neuropathy
The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON
UK audit explores reasons patients skip diabetic retinopathy screenings
Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening
The year in review, with our friends from Modern Retina
Hot topics around the globe, from clinical trials to the solar eclipse
Ophthalmology Times wraps up a year of innovation and insight
Highlights from the year, courtesy of our colleagues at Ophthalmology Times
Looking back at 2024 with our colleagues from Optometry Times
The top therapeutic advancements in myopia, diabetes, dry eye and more
Wrapping up another year in eye care: 2024 in review
Trending topics and milestone stories from our year in ophthalmology
Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
See the best of our print edition with the 2024 cover story roundup
Our top 10 print stories highlight the core content concepts we explored this year
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
Shining new light on ocular surface care
Low-level light therapy for dry eye disease and chalazion
A history of the femtosecond laser in the United States and Europe
The timeline demonstrates international innovation and collaboration
Balancing the promises and challenges of artificial intelligence
Sophisticated programmes require an evolving mindset
EssilorLuxottica announces agreement for acquisition of Espansione Group
Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology
A neurologist shares his warning about recurrent optic neuritis attacks and NMOSD
Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)
EMA CHMP issues positive opinion for aflibercept biosimilar, two other candidates from Celltrion
The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)
Putting diagnostic accuracy to the test
A confirmed diagnosis of familial exudative vitreoretinopathy aids in several aspects of patient management
European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringe
The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion
AMD-HALT programme receives Eurostars grant for continued investigation of dry AMD gene therapy platform
Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union
Investigators report findings on serum inflammatory biomarkers in patients with macular oedema
A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO
Myopia control study demonstrates 4-year results of Diffusion Optics Technology
The research findings supported the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children
Diabetic eye disease: Where are we now?
Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications
Case report: retinopathy associated with the use of hair dye aromatic amines
Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy
Industry updates from Floretina ICOOR 2024
The annual meeting brought fourth announcements and insights from companies in the retina care space
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion
Don’t miss our editorial advisory board members at the Floretina/ICOOR meeting
EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of care
Breakthrough technologies are raising the ceiling for functional visual outcomes
